 Heron Therapeutics, Inc. Nasdaq: HRTX, a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that it received a Complete Response Letter CRL from the U.S. Food and Drug Administration FDA on June 26, 2020 regarding its New Drug Application NDA for HTX-011 for the management of postoperative pain. 